Navigation Links
ViroPharma's Buccolam® (Midazolam, Oromucosal Solution) Granted European Marketing Authorization for Treatment of Acute Seizures
Date:9/6/2011

nating pediatric convulsive seizures.

The approval of Buccolam follows the positive opinion adopted by the Committee for Medicinal Products for Human Use (CHMP) in June 2011. Buccolam is now approved throughout all the Member States of the European Union (EU) as well as in the European Economic Area (EEA), namely Norway, Iceland and Liechtenstein.

"The marketing authorization for Buccolam in Europe is an important step towards addressing the need of parents and carers in the community for a rapidly-acting, effective and socially acceptable rescue medication for emergency treatment to terminate prolonged, acute convulsive seizures in children and adolescents," commented Thierry Darcis, M.D., ViroPharma's vice president, general manager, Europe. "We look forward to providing for the evolving needs of patients, which is our priority throughout our global organization, and we look forward to working closely with physicians across Europe as we launch Buccolam into the European markets."

A Pediatric Use Marketing Authorization (PUMA) is a new type of centralized marketing authorization procedure requested for medicines already authorized but no longer covered by intellectual property rights and exclusively developed for use in children. Medicines awarded a PUMA benefit from 10 years of market protection.

About Buccolam® (Midazolam, Oromucosal Solution)

Buccolam is oral midazolam provided in an individual dose formulation for buccal delivery.  It is provided as a convenient, portable, ready to use, pre-filled syringe containing an age-specific dose. Buccolam is approved throughout the European Union and the EEA for treatment of prolonged, acute, convulsive seizures in infants, toddlers, children and adolescents, from three months to less than 18 years of age.  Buccolam should only be used by parents/carers where the patient has been diagnosed to have epilepsy.  For infants between 3-6 months of age, trea
'/>"/>

SOURCE ViroPharma Incorporated
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related medicine technology :

1. ViroPharma Announces Positive CHMP Opinion for Buccolam® (Midazolam, Oromucosal Solution) in the European Union
2. Nautilus Neurosciences and Tribute Pharmaceuticals Announce Exclusive Canadian License for CAMBIA™ (diclofenac potassium for oral solution) for the Acute Treatment of Migraine
3. Nautilus Neurosciences and Mission Pharmacal Announce Exclusive Co-Promotion Agreement for CAMBIA™ (diclofenac potassium for oral solution) for the Acute Treatment of Migraine to the Womens Health Market
4. Enox Biopharma, Inc. Will Be Granted its Foundation Patent
5. Winner Medical Granted the COTTON USA Mark
6. Patent Granted for Simbionix Procedure Rehearsal Studio™
7. XGEVA® (Denosumab) Granted Marketing Authorization in the European Union
8. China Botanic Pharmaceutical Granted China Patent for Siberian Ginseng Extraction Process
9. ACT Granted EU Orphan Medicinal Product Designation for hESC-Derived RPE Cells for Treatment of Stargardts Disease
10. ViroPharmas Cinryze® (C1 Inhibitor [Human]) Granted European Marketing Authorization for Hereditary Angioedema (HAE)
11. Enox Biopharma, Inc. Will Be Granted a Patent for the Delivery of Therapeutic Agents From Within Medical Devices
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:3/27/2015)... , March 27, 2015 The Temple Health & ... to a 5,000-square-foot building at 1802 South First St. in ... designated by the City of Temple ... White and the Central Texas Veterans Health Care System, the ... space to early stage biotechnology and life science companies. ...
(Date:3/27/2015)... XRpro Sciences, Inc., a provider of ... services which features high throughput transporter and ion ... results for the year ended December 31, 2014. ... XRpro Sciences commented, "We have completed a number ... to commercial stage in large part by achieving ...
(Date:3/27/2015)... BROOKFIELD, Wis. , March 27, 2015 /PRNewswire/ ... 40,000 unit shipments of incontinence devices for women. ... terrific, but the most gratifying part is the ... receive from women whose lives have been positively ... , president of InControl. InControl recently ...
Breaking Medicine Technology:Temple Health & Bioscience District Relocates, Offers Office And Lab Space To Biotech Companies 2XRpro Sciences Announces Fiscal 2014 Financial Results 2XRpro Sciences Announces Fiscal 2014 Financial Results 3XRpro Sciences Announces Fiscal 2014 Financial Results 4InControl Medical Surpasses 40,000 Shipments Of Incontinence Devices For Women 2
... RONKONKOMA, N.Y., March 14, 2011 NBTY, Inc. (Nasdaq: ... manufacturer and marketer of nutritional supplements in the United ... a conference call to review its fiscal first quarter ... 2011 at 10:00 AM (ET).  These results are posted ...
... health division of Eli Lilly and Company (NYSE: ... an irrevocable, unconditional offer to acquire the animal health ... Company. The two companies have notified the appropriate European ... Janssen,s animal health business is primarily European-focused, targeting disease ...
Cached Medicine Technology:NBTY to Webcast Fiscal First Quarter Conference Call 2Lilly Makes an Irrevocable Offer to Acquire Janssen Animal Health 2Lilly Makes an Irrevocable Offer to Acquire Janssen Animal Health 3
(Date:3/28/2015)... March 28, 2015 India Network ... is made available to all visitors who purchase the ... All members are encouraged to purchase the insurance program ... lack of proper coverage for pre-existing medical conditions. Parents ... or two medical conditions with serious consequences to their ...
(Date:3/28/2015)... March 28, 2015 One in three ... to research presented today at the American Orthopaedic Society ... study examined the long term success of surgery for ... examined survey data from 242 patients who underwent ACL ... P. Roe, MBBS, FRACS, from North Sydney Orthopaedic and ...
(Date:3/28/2015)... Genomic medicine experts have sequenced the ... the first time, key information for understanding and treating ... newly posted story on the Surviving Mesothelioma website. ... Columbia, the British Columbia Cancer Agency, and PhenoPath lab ... molecular alterations and mutations that can lead to ...
(Date:3/28/2015)... 2015 Healthpointe’s otolaryngologists, medical practitioners who ... disorders, are now offering a wide variety of ... is characterized by the presence of phantom sounds or ... tinnitus is a prevalent symptom that can arise due ... non-fatal, tinnitus can impede a person’s quality of life. ...
(Date:3/28/2015)... 2015 Purity Products®, a leading ... the release of their revolutionary new weight loss ... randomized, double-blind, placebo-controlled clinical studies to be effective ... size. MuffinStop™ is a combination of two traditionally ... fused together to create one of the most ...
Breaking Medicine News(10 mins):Health News:India Network Health Insurance Today Announces New Eligibility Criteria for Pre-existing Condition Health Insurance Coverage for Visitors to the United States 2Health News:India Network Health Insurance Today Announces New Eligibility Criteria for Pre-existing Condition Health Insurance Coverage for Visitors to the United States 3Health News:Young Athletes at Greater Risk for Re-Injury after ACL Surgery 2Health News:New Genomics Research May Help Doctors Tailor Mesothelioma Treatment, According to Surviving Mesothelioma 2Health News:Healthpointe now Offering Tinnitus Treatments in Clinics throughout Southern California 2Health News:Purity Products Releases Revolutionary New Weight Loss Product, MuffinStop™ 2
... ... disabled car and killed the driver. , ... New York, NY (PRWEB) February 9, 2010 -- A truck driver killed a mother of two ... His truck crashed into her disabled car on the New York State Thruway. The accident happened ...
... anxiety and depression are most likely to use a shade ... the open access journal BMC Medical Research Methodology ... Wheel, which can be used to study people,s preferred pigment ... Professor of Medicine and Gastroenterology at University Hospital South Manchester, ...
... the two drugs together, researchers say , , MONDAY, ... who take both tamoxifen and the antidepressant Paxil may ... effectiveness, Canadian researchers report. , "Paxil can deprive women ... used in combination with tamoxifen for a long time," ...
... CLEARWATER, Fla. , Feb. 8 Lincare Holdings Inc. (Nasdaq: ... year ended December 31, 2009 . , For the quarter ended ... compared with net revenues of $415.1 million for the fourth ... revenues in the fourth quarter of 2009 was comprised of 13% internal ...
... by Pier Paolo Pandolfi, at Beth Israel Deaconess Medical ... senescence (i.e., irreversible arrest of cell growth) and determined ... development and growth in mice. Previous work by ... Pten leads to a senescence response that opposes tumorigenesis. ...
... predict the progression to dementia in older adults with ... decisions) but not in those with memory dysfunction, according ... Archives of Neurology, one of the JAMA/Archives journals. ... risk factor for the development of dementia in late ...
Cached Medicine News:Health News:New York Truck Driver Watching Porn Kills Mother, Appalls Personal Injury Lawyers Such As David Perecman 2Health News:New York Truck Driver Watching Porn Kills Mother, Appalls Personal Injury Lawyers Such As David Perecman 3Health News:Depressed people feel more gray than blue 2Health News:Paxil Blocks Tamoxifen, Lowers Survival Odds Against Breast Cancer 2Health News:Paxil Blocks Tamoxifen, Lowers Survival Odds Against Breast Cancer 3Health News:Lincare Holdings Inc. Announces Fourth Quarter and Year Ended 2009 Financial Results 2Health News:Lincare Holdings Inc. Announces Fourth Quarter and Year Ended 2009 Financial Results 3Health News:Lincare Holdings Inc. Announces Fourth Quarter and Year Ended 2009 Financial Results 4Health News:Lincare Holdings Inc. Announces Fourth Quarter and Year Ended 2009 Financial Results 5Health News:Lincare Holdings Inc. Announces Fourth Quarter and Year Ended 2009 Financial Results 6Health News:Lincare Holdings Inc. Announces Fourth Quarter and Year Ended 2009 Financial Results 7Health News:Lincare Holdings Inc. Announces Fourth Quarter and Year Ended 2009 Financial Results 8Health News:Lincare Holdings Inc. Announces Fourth Quarter and Year Ended 2009 Financial Results 9Health News:Lincare Holdings Inc. Announces Fourth Quarter and Year Ended 2009 Financial Results 10Health News:Hypertension may predict dementia in older adults with certain cognitive deficits 2
... reference laboratory and a worldwide leader in ... an extensive test menu of highly complex ... anatomic pathology. Owned by the University of ... half of the nation's university teaching hospitals ...
... Laboratories is a national reference laboratory and ... and development. ARUP offers an extensive test ... tests in clinical and anatomic pathology. Owned ... clients include more than half of the ...
... ARUP Laboratories is a national reference ... laboratory research and development. ARUP offers an ... unique medical tests in clinical and anatomic ... ARUP Laboratories' clients include more than half ...
... ARUP Laboratories is a national reference laboratory ... research and development. ARUP offers an extensive ... medical tests in clinical and anatomic pathology. ... Laboratories' clients include more than half of ...
Medicine Products: